Repositorio Digital de la UPF
Publicación
Artículo científico (JournalArticle)
Targeting dysregulated CB1 receptors in a Down syndrome mouse model improves neurological outcomes
INTRODUCTION: Down syndrome (DS) is the most common genetic cause of intellectual disability, affecting cognitive function and increasing the risk of early-onset Alzheimer's disease (AD). The endocannabinoid system may serve as a therapeutic target for cognitive deficits by inhibiting cannabinoid type-1 receptor (CB1R) function. METHODS: CB1R expression was analyzed in the hippocampi of aged DS-associated AD (DSAD) individuals and middle-aged Ts65Dn mice. Long-term oral treatment with the CB1R antagonist rimonabant was used to assess its effects on memory and neuroinflammation in the Ts65Dn mouse model of DS. RESULTS: CB1R expression was significantly increased in both aged DSAD subjects (specifically in the dentate gyrus and CA2 posterior hippocampal subregions) and Ts65Dn mice. Long-term rimonabant treatment improved memory performance, normalized microglial morphology, and reduced plasma inflammatory markers in trisomic mice without preventing neuron decline. DISCUSSION: These findings suggest that sustained CB1R inhibition may enhance cognitive function by modulating neuroinflammation, highlighting its therapeutic potential for cognitive impairments in DS. Highlights: Cannabinoid type-1 receptor (CB1R) expression is increased in the posterior hippocampus of aged Down syndrome (DS) subjects and Ts65Dn mice. Long-term rimonabant treatment enhances memory in middle-aged Ts65Dn mice. CB1R inhibition shifts neuroinflammatory features in Ts65Dn mice. CB1R inhibition does not halt noradrenergic/cholinergic neurodegeneration in Ts65Dn. CB1R inhibition presents potential for memory improvement in DS-related deficits., Ministerio de Ciencia, Innovación y Universidades, Grant/Award Numbers:RTI2018-099282-B-I00, PID2021-123482OB-I00-/MICIN/AEI/10.13039/501100011033/FEDER,PID2020- 120029GB-I00/MICIN/AEI/10.13039/501100011033; Fondation Jérôme Lejeune, Grant/Award Numbers:1896_GRT-2019B, #2416_GRT-2024B; Bright Focus foundation, Grant/Award Number:CA2018010; Ministerio de Sanidad, Servicios Sociales e Igualdad, Grant/Award Number:RD16/0017/0020; Departament de Recerca i Universitats, Generalitat de Catalunya,Grant/Award Number: 2017SGR-669 Departament d'Economia i Coneixement, Generalitat de Catalunya, Grant/Award Number: 2017SGR-138; Institució Catalana de Recerca i Estudis Avançats, ICREA-Acadèmia2021